ResearcherHefei University of TechnologyActive in the last 2 years

Xiaoxiao Yang

ORCID-verified (high confidence)As of 13 November 2026

Matched on ORCID iD 0000-0003-0290-2844.

Their work

Counts cover pancreatic cancer work only: a researcher’s other papers, trials and grants are not in these records.

Pancreatic cancer papers: 1 (first author 0, last author 1)
Pancreatic cancer trials: 0
Pancreatic cancer grants: 0
Collaborators: 2

Papers, trials and grants by year

2024: 1 paper

Papers 1

Inhibition of Nogo-B reduces the progression of pancreatic cancer by regulation NF-κB/GLUT1 and SREBP1 pathways. Last author DOI 10.1016/j.isci.2024.109741 ↗

Closest collaborators

The 2 strongest of 2 ranked by shared papers, trials and grants, with recent and small-team work weighing most.

Lingling Wei · 1 shared paper, 2024
- Paper Inhibition of Nogo-B reduces the progression of pancreatic cancer by regulation NF-κB/GLUT1 and SREBP1 pathways. DOI 10.1016/j.isci.2024.109741 ↗
Tianxiang Wang · 1 shared paper, 2024
- Paper Inhibition of Nogo-B reduces the progression of pancreatic cancer by regulation NF-κB/GLUT1 and SREBP1 pathways. DOI 10.1016/j.isci.2024.109741 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (the fewest links first, then the links with the most shared work). Built from public records only; no contact details are kept.